For the Inventor, By the Inventor

Enter assignee name

Shionogi Company Limited

Calculating rank

USPTO Granted Patents = 1,001

% Expired Patents = 23.0

CIPO Patents = 46

EPO Patents = 147

Trademarks = 30

Forward Citations = 6,070

Loading Chart...

Loading Chart...

1,060 inventors (with patents filed for the assignee):

Wataru Nagata (49 out of 51 patents)

Hiroyuki Kai (48 out of 48 patents)

Mitsuaki Ohtani (48 out of 50 patents)

4. Yoshio Hamashima (37 out of 38 patents)

5. Masayuki Narisada (35 out of 37 patents)

6. Teruji Tsuji (33 out of 34 patents)

7. Mitsuru Yoshioka (32 out of 33 patents)

8. Yoshiyuki Taoda (31 out of 32 patents)

9. Moriyasu Masui (30 out of 30 patents)

10. Fumihiko Watanabe (27 out of 27 patents)

11. Akira Takase (27 out of 27 patents)

12. Kentaro Hirai (25 out of 28 patents)

13. Brian Alvin Johns (23 out of 56 patents)

14. Masaru Ogata (23 out of 24 patents)

15. Tsunetoshi Honma (21 out of 21 patents)

Core Competencies:

MGAT-2 Inhibitors

Pharmaceutical Compositions

Antiviral Agents

Solid Dosage Forms

HIV Integrase Inhibitors

TrkA Inhibitory Activity

Monoclonal Antibodies

Dopamine D3 Antagonists

Heterocyclic Derivatives

Polycyclic Pyridone Derivatives

Stability Enhancements

Clinical Trial Analysis

1,001 patents: Sort by Forward Citations

1. 12455270 - Mesh for dissolution test (2025-10-28),

2. 12454533 - Fused ring derivative having MGAT-2 inhibitory activity (2025-10-28),

3. 12427156 - Solid dosage form having excellent stability (2025-09-30),

4. 12400468 - Program generation assisting system for assisting generation of program for analyzing clinical trial (2025-08-26),

5. 12351804 - Production method for bifurcated lipid-linked oligonucleotide, and intermediate (2025-07-08),

6. 12350377 - Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives (2025-07-08),

7. 12312327 - Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same (2025-05-27),

8. 12285526 - Nanoparticle composition with reduced contaminant and production method thereof (2025-04-29),

9. 12227509 - Dihydropyrazolopyrazinone derivative having MGAT2 inhibitory activity (2025-02-18),

10. 12139489 - Polycyclic carbamoylpyridone derivative (2024-11-12),

11. 12098151 - Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative (2024-09-24),

12. 12064438 - Pharmaceutical preparation excellent in light stability and dissolution property (2024-08-20),

13. 12024519 - Fused ring derivative having MGAT-2 inhibitory activity (2024-07-02),

14. 11932696 - Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells (2024-03-19),

15. 11925648 - Solid dosage form having excellent stability (2024-03-12),

Company Overview

Shionogi Company Limited, headquartered in Osaka, Japan, specializes in the development and manufacturing of pharmaceutical compositions. The company is recognized for its innovative research in various therapeutic areas, including antiviral agents and HIV integrase inhibitors. Shionogi's core technology topics encompass MGAT-2 inhibitors, solid dosage forms, and monoclonal antibodies, reflecting its commitment to addressing unmet medical needs through advanced pharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

1,001 Patents

#27 in Osaka

#230 in Japan

#1,030 in the World

Shionogi Company Limited

Forward Citations = 6,070

1,060 inventors:

Wataru Nagata (49 out of 51 patents)

Hiroyuki Kai (48 out of 48 patents)

Mitsuaki Ohtani (48 out of 50 patents)

4. Yoshio Hamashima (37 out of 38 patents)

5. Masayuki Narisada (35 out of 37 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Shionogi Company Limited. Retrieved from https://idiyas.com/company/shionogi-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…